<DOC>
	<DOCNO>NCT02935517</DOCNO>
	<brief_summary>This non-randomized , open-label , Phase 1/2 study safety efficacy AGTC-402 , administer one eye subretinal injection individual achromatopsia cause mutation CNGA3 gene . The primary study endpoint safety secondary study endpoint efficacy .</brief_summary>
	<brief_title>Safety Efficacy Trial AAV Gene Therapy Patients With CNGA3 Achromatopsia</brief_title>
	<detailed_description>This non-randomized , open-label , Phase 1/2 study safety efficacy AGTC-402 administer one eye subretinal injection individual achromatopsia cause mutation CNGA3 gene . The primary study endpoint safety secondary study endpoint efficacy . Subjects enrol sequentially four group . Subjects Groups 1 , 2 3 18 55 year age , inclusive , receive low , middle high dose study agent . Subjects Group 4 6 55 year age , inclusive , receive maximum tolerate dose identified Groups 1 , 2 3 . Safety monitor evaluation ocular non ocular adverse event hematology clinical chemistry parameter . Efficacy parameter include visual acuity , light discomfort testing , color vision , static visual field , ERG , adaptive optic retinal image OCT .</detailed_description>
	<mesh_term>Color Vision Defects</mesh_term>
	<criteria>1 . Retinal disease consistent diagnosis achromatopsia document mutation allele CNGA3 gene ; 2 . Between 18 55 year age , inclusive , Groups 1 , 2 3 6 55 year age , inclusive , Group 4 ; 3 . Able perform test visual retinal function ; 4 . Visual acuity study eye well 55 ETDRS letter ( Snellen equivalent 20/80 ) base average two examination baseline visit ; 5 . Acceptable laboratory parameter ; 6 . For female childbearing potential : A negative pregnancy test within 2 day administration study agent . 1 . Presence myopia , opinion Investigator , may create increased surgical risk subject study eye ; 2 . Evidence degenerative myopia study eye ; 3 . Preexisting eye condition would contribute vision loss either eye increase risk subretinal injection study eye .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Color vision deficiency</keyword>
	<keyword>Color vision defect</keyword>
	<keyword>Vision disorder</keyword>
	<keyword>Sensation disorder</keyword>
	<keyword>Neurologic manifestation</keyword>
	<keyword>Nervous system disease</keyword>
	<keyword>Eye disease</keyword>
	<keyword>Signs symptom</keyword>
</DOC>